Inc.

Telephonic Interview

A telephonic interview was conducted between the Examiner and the undersigned on March 11, 2003. During the interview the status of the claims was clarified. In particular, it was agreed that Claims 1-8, 10-17, 20, 21, 28 and 29 are allowable, Claim 9 has been cancelled and Claims 18, 19, 22-27, 30 and 31 stand rejected. In addition, it was confirmed that a "Statement of Loss of Original Patent" was filed by both Assignees (Columbia University and Sloan-Kettering Institute for Cancer Research) on October 10, 2002 in order to comply with 37 C.F.R. § 1.178. Applicants thank the Examiner for conducting the telephonic interview and forwarding the Interview Summary, which outlined the status of the claims, on an expedited basis via facsimile.

Please amend the application as follows:

In the Claims

Please amend pending Claims 18, 19 (newly added upon filing) and 30 (newly added, October 10, 2002) to read as shown below.

Please cancel Claims 22-27 and 31.

In accordance with 37 C.F.R. §1.173 the amendments are shown with bracketing and underlining relative to the claim of the issued patent in effect as of the date of filing of the Reissue Application. The amendments to pending Claims 18, 19 and 30, which were newly added upon filing (Claims 18 and 19) and in Amendment A filed on October 10, 2002 (Claim 30), are discussed in the Remarks Section in accordance with MPEP § 1453.




Inc.

A compound having the structure:

wherein n is an integer selected from the group consisting of 5, 6, 7 and 8.

<u> 19.</u> A pharmaceutical composition comprising a therapeutically effective amount of a compound having the structure:



wherein n is an integer selected from the group consisting of 5, 6, 7 and 8; and a pharmaceutically acceptable carrier.



